### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: July 3, 2025

Commission File Number: 001-38974

# **BIOPHYTIS S.A.**

(Translation of registrant's name into English)

Stanislas Veillet
Biophytis S.A.
Sorbonne University—BC 9, Bâtiment A 4ème étage
4 place Jussieu
75005 Paris, France
+33 1 44 27 23 00
(Address of principal executive office)

(Address of principal executive office)		
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:		
⊠ Form 20-F □ Form 40-F		
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): □		
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): □		

On June 30, 2025, Biophytis S.A. issued a press release announcing that it is not in a position to publish its 2024 annual accounts on the previously scheduled date. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.

## EXHIBIT LIST

Exhibit		Description
<u>99.1</u>	Press Release dated June 30, 2025.	

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: July 3, 2025

## BIOPHYTIS S.A.

By:/s/ Stanislas Veillet

Name: Stanislas Veillet

Title: Chairman and Chief Executive Officer



Press release

#### Information on the Annual Financial Statements

Paris (France) and Cambridge (Massachusetts, USA), June 30, 2025 – 10:30 PM (CET) – Biophytis SA (Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases announces that it is not in a position to publish its 2024 annual accounts on the previously scheduled date.

Biophytis will publish its 2024 annual accounts as soon as possible, by Monday, July 7 at the latest.

#### **About BIOPHYTIS**

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.

#### Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements.

Page 1 sur 2



Press release

Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether because of new information or otherwise, except as required by law.

### **Biophytis Contacts**

<u>Investor Relations</u> <u>Investors@biophytis.com</u>

#### **US Investors**

<u>Pascal Nigen – Alpha Bronze</u> <u>pnigen@alphabronzellc.com</u>

#### Media contacts

<u>Antoine Denry: antoine.denry@taddeo.fr - +33 6 18 07 83 27</u> <u>Inès de Mandiargues: ines.demandiargues@taddeo.fr - +33 6 16 16 51 78</u>

Page 2 sur 2